MedTrace Logo

Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization

NCT00297661 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1012

Last updated 2006-10-20

No results posted yet for this study

Summary

Context: Sirolimus-eluting stents and paclitaxel-eluting stents, as compared with bare-metal stents, reduce the risk of restenosis. It is unclear whether there are differences in safety and efficacy between the two types of drug-eluting stents.

Objective: To determine differences in safety and efficacy between sirolimus and paclitaxel eluting stents.

Conditions

Interventions

DEVICE

Sirolimus-eluting stent

DEVICE

Paclitaxel-eluting stent

Sponsors & Collaborators

  • University of Zurich

    collaborator OTHER

  • University of Bern

    lead OTHER

Principal Investigators

  • Stephan Windecker, MD · Department of Cardiology, University Hospital Bern

  • Peter Juni, MD · Department of Social and Preventive Medicine, University of Bern

  • Bernhard Meier, MD · Department of Cardiology, University Hospital Bern

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00297661 on ClinicalTrials.gov